Canakinumab for the treatment of hyperimmunoglobulin D syndrome

Judith Sánchez-Manubens, Estibaliz Iglesias, Jordi Anton

Research output: Contribution to journalArticleResearch

4 Citations (Scopus)


© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe form). Patients have recurrent inflammatory attacks with high fever, gastrointestinal symptoms, lymphadenopathy, splenomegaly, arthralgia, rash, pharyngitis, aphtosis and constitutional complaints. Heightened understanding of molecular mechanisms in monogenic autoinflammatory disorders has provided tools for targeted treatment. HIDS is an extrinsic inflammasomopathy and is responsive to anti-IL-1 therapies, such as the recombinant IL-1-receptor antagonist anakinra, the monoclonal antibody against IL-1b canakinumab (CAN), and the recombinant IL-1R fusion protein rilonacept. Areas covered: CAN is a human monoclonal anti-IL-1β antibody that binds with high affinity and neutralizes the activity of IL-1 β. Both observational registries and some case reports have seemed promising in the efficacy of CAN in the HIDS treatment. Two clinical trials have corroborated CAN as an effective and safe drug. Expert commentary: CAN is effective and safe for the treatment of HIDS patients. Some data suggest these patients may need higher dosage or shorter dosing interval than other AIDs, to achieve and maintain complete clinical and laboratory response. Reported adverse events were mild, most often non-complicated infections.
Original languageEnglish
Pages (from-to)215-220
JournalExpert Review of Clinical Immunology
Publication statusPublished - 4 Mar 2019


  • biologics
  • Canakinumab
  • hyperimmunoglobulinemia D
  • interleukin 1 inhibitor
  • mevalonate kinase deficiency


Dive into the research topics of 'Canakinumab for the treatment of hyperimmunoglobulin D syndrome'. Together they form a unique fingerprint.

Cite this